CCC Diagnostics LLC

1
CCC Diagnostics LLC

• Saving Lives Life Savings
• A Personalized Approach to Anticancer Therapy
• www.CCCDiag.com

2
The Challenge

• Cancer is a Highly Individualized Disease
• Effective Treatment Relies on Drug Selection
• Only 20-30 Effective
• Significant Side Effects
• Annual Costs can Exceed 30,000 per Patient
• No Standard Procedures
• Selecting Optimal Treatment
• Developing Personalized Regimens

3
The SolutionDrug Response Indicator Test (DRIT)

• Diagnostic Service for Individual Patients
• Selects Effective Drug Treatments
• Optimizes Use of Time Window for Treatment
• Reduces Patients Side Effects
• Saves Significant Treatment Costs

4
The Company CCC Diagnostics LLC

• Leadership
• - Core Group of former Johns Hopkins
  Researchers
• Mission
• - Create a Drug Response Indicator Index
• - Establish Personalized Anticancer Treatment
  Regimens
• Core Technology
• - Proprietary Platform Technology
• - Drug Response Indicator Test (DRIT)
• - Applications for 6 Cancer Groups
• Breast. Lung, Colon, Gastric, Pancreas
  Esophagus

5
The TechnologyDrug Response Indicator Test

• Proprietary Platform Technology
• Computerized Fluorescence Microscopy
• Measures 7 Drug Response Indicators Levels
• Simultaneous Analysis of 5 Biomarkers
• Measures Drug Resistance/Sensitivity of Tumor
• Establishes Standardized Measurements
• Analysis based on up to 1000 Tumor Cells

6
The Methods

• Immunofluorescent Application
• Antibody Labeling
• Distinct Emission Wavelengths
• 5 Fluorescent Signals per Cell

7
The Six Cancer Groups

• Drug Response Indicators

8
The Competing Technologies
9
The DRIT Advantage

• Enables Personalized Treatment Regimen
• One Test details Tumor Response for
• 7 FDA- Approved Anticancer Drugs
• Determines Probability of Drug Sensitivity
• Predicts Duration of Effective Drug Treatment
• Addresses New Chemotherapeutic Drugs
• Adaptable to Different Cancers Biomarkers

10
The Clinical Verification

• RETROSPECTIVE CORRELATION STUDY
• BREAST CANCER
• Clinical Partners
• - U of MD Hospital, Walter Reed, MedStar
  System
• Patient Population
• - 200-300 Patients Establishes
  Statistical Significance
• Breast Cancer Results
• - 65 patients analyzed
• - 95 accuracy in prediction
• Professional Conferences
• - Accepted Abstracts Presentations

11
The Clinical Verification

• RETROSPECTIVE CORRELATION STUDY
• LUNG CANCER
• Clinical Partners
• U of MD Hospital, MedStar System
• Patient Population
• - 200-300 Patients Establishes
  Statistical Significance
• Current Results
• - 27 patients analyzed
• - Positive predictive value (0.88)
• One Abstract submitted

12
The Market

• Cancer In-Vitro Diagnostics (IVDs)
• - 4.1B Annual Worldwide Market
• - Overall Growth Rate 13
• - Projected to Exceed 7.4B by 2009
• Cancer Statistics
• - 47 for Males 38 for Females
• - 1.4 million new cases all cancers
• - 570,000 deaths annually all cancers
• - breast cancer 214,640 new cases/year
• - lung cancer 175,00 new cases/year
• The Worldwide Market for Cancer Diagnostics
  Kalorama 2005

13
The Business Model

• In House Diagnostic Service
• - Homebrew designation
• - CAP, CLIA certifications
• - Testing for oncologists
• Licensing Services
• - large clinical labs (Quest ,etc)
• - health provider systems (VA etc)
• FDA Approval Medical Reimbursement
• - increased market - revenue growth

14
The Contacts

• Paul O.P. Ts'o, Ph.D.,
• Managing Director Founder
• paul_at_cccdiag.com
• Rosel Halle
• Director of Business Development
• rosel_at_cccdiag.com
• 410-633-4885 www.CCCDiag.com